These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14766970)

  • 41. Aggregation and dispersion characteristics of calcium oxalate monohydrate: effect of urinary species.
    Christmas KG; Gower LB; Khan SR; El-Shall H
    J Colloid Interface Sci; 2002 Dec; 256(1):168-74. PubMed ID: 12505509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization.
    Su Y; Li S; Li X; Zhou JY; Chauhan VP; Li M; Su YH; Liu CM; Ren YF; Yin W; Rimer JD; Cai T
    Adv Sci (Weinh); 2024 Jun; 11(21):e2400642. PubMed ID: 38647258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of a protein inhibitor isolated from human renal stone matrix in urolithiasis.
    Aggarwal S; Tandon C; Forouzandeh M; Singla SK; Kiran R; Jethi RK
    Indian J Biochem Biophys; 2005 Apr; 42(2):113-7. PubMed ID: 23923571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi.
    McKee MD; Nanci A; Khan SR
    J Bone Miner Res; 1995 Dec; 10(12):1913-29. PubMed ID: 8619372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicolor imaging of calcium-binding proteins in human kidney stones for elucidating the effects of proteins on crystal growth.
    Tanaka Y; Maruyama M; Okada A; Furukawa Y; Momma K; Sugiura Y; Tajiri R; Sawada KP; Tanaka S; Takano K; Taguchi K; Hamamoto S; Ando R; Tsukamoto K; Yoshimura M; Mori Y; Yasui T
    Sci Rep; 2021 Aug; 11(1):16841. PubMed ID: 34446727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides.
    Chan BP; Vincent K; Lajoie GA; Goldberg HA; Grohe B; Hunter GK
    Colloids Surf B Biointerfaces; 2012 Aug; 96():22-8. PubMed ID: 22503630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of various modifiers on calcium oxalate crystallization.
    Kulaksizoglu S; Sofikerim M; Cevik C
    Int J Urol; 2007 Mar; 14(3):214-8. PubMed ID: 17430258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of calcium oxalate dihydrate growth by phosphorylated osteopontin peptides.
    Chien YC; Mansouri A; Jiang W; Khan SR; Gray JJ; McKee MD
    J Struct Biol; 2018 Nov; 204(2):131-144. PubMed ID: 30016645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of inhibition mechanisms of glycosaminoglycans on calcium oxalate monohydrate crystals by atomic force microscopy.
    Shirane Y; Kurokawa Y; Miyashita S; Komatsu H; Kagawa S
    Urol Res; 1999 Dec; 27(6):426-31. PubMed ID: 10651130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization.
    Evan AP; Coe FL; Rittling SR; Bledsoe SM; Shao Y; Lingeman JE; Worcester EM
    Kidney Int; 2005 Jul; 68(1):145-54. PubMed ID: 15954903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrinsically Disordered Osteopontin Fragment Orders During Interfacial Calcium Oxalate Mineralization.
    Lu H; Ng DYW; Lieberwirth I; Weidner T; Bonn M
    Angew Chem Int Ed Engl; 2021 Aug; 60(34):18577-18581. PubMed ID: 34118104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation.
    Cerini C; Geider S; Dussol B; Hennequin C; Daudon M; Veesler S; Nitsche S; Boistelle R; Berthézène P; Dupuy P; Vazi A; Berland Y; Dagorn JC; Verdier JM
    Kidney Int; 1999 May; 55(5):1776-86. PubMed ID: 10231440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced crystallization inhibition by urine from men with nephrolithiasis.
    Asplin JR; Parks JH; Chen MS; Lieske JC; Toback FG; Pillay SN; Nakagawa Y; Coe FL
    Kidney Int; 1999 Oct; 56(4):1505-16. PubMed ID: 10504502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model.
    Senzaki H; Yasui T; Okada A; Ito Y; Tozawa K; Kohri K
    Urol Res; 2004 Jun; 32(3):223-8. PubMed ID: 15064876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calcium oxalate crystal growth in the presence of mucin.
    Akbarieh M; Tawashi R
    Scanning Microsc; 1991 Dec; 5(4):1019-26; discussion 1026-7. PubMed ID: 1822027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis.
    Coe FL; Nakagawa Y; Asplin J; Parks JH
    Miner Electrolyte Metab; 1994; 20(6):378-84. PubMed ID: 7783700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein.
    Schwille PO; Schmiedl A; Manoharan M
    Clin Chem Lab Med; 2004 Mar; 42(3):283-93. PubMed ID: 15080561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
    Pak CY; Peterson R
    Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uropontin in urinary calcium stone formation.
    Hoyer JR
    Miner Electrolyte Metab; 1994; 20(6):385-92. PubMed ID: 7783701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.